Pages

▼
27 February 2026

T 0749/23 - Any embodiment as starting point (Mite composition)

›
Key points Claim 1 of AR-3 at issue  “is for a composition comprising (i) a population of individuals from a Phytoseiid mite species, (ii) a...
3 comments:
25 February 2026

T 1396/23 - 2nd medical use claim for foodstuff

›
Key points Claim 1: “Composition comprising polysaccharides and whey protein micelles [provided as a complex, a so-called WPM complex] for u...
23 February 2026

T 1601/22 - More than a year for the written decision

›
Key points This decision (by Board 3.3.04) was taken during oral proceedings on 10.10.202 4 . The written decision was issued on 23.12.202 5...
1 comment:
20 February 2026

T 1902/23 - Twelve documents as the CPA

›
Key points “The [proprietor/respondent] argued that D11 should be considered as the closest prior art for assessing inventive step, contrary...
18 February 2026

T 1909/23 - 2nd medical use claim for individualized RNA cancer vaccine

›
Key points III. Claim 1 of the patent reads as follows: "1. An individualized cancer vaccine for use in a method of treating a cancer p...
16 February 2026

T 1571/23 - No harmless error rule?

›
Key points The OD revoked the patent. The proprietor appeals and requests that the impugned decision be set aside because of an alleged subs...
13 February 2026

T 1113/24 - OD should have heard witnesses

›
Key points The opposition is based on an alleged public prior use. The OD rejected the opposition. The opponent appeals. The OD had refused ...